Simulations Plus (NASDAQ:SLP) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Simulations Plus (NASDAQ:SLP) released its earnings results on Wednesday. The technology company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.02, Briefing.com reports. The firm had revenue of $18.70 million for the quarter, compared to the consensus estimate of $19.73 million. Simulations Plus had a return on equity of 7.80% and a net margin of 14.36%. The firm’s revenue was up 19.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.18 EPS. Simulations Plus updated its FY25 guidance to $1.07 to $1.20 EPS and its FY 2025 guidance to 1.070-1.200 EPS.

Simulations Plus Stock Performance

Shares of SLP traded down $0.28 during trading hours on Friday, hitting $30.68. The stock had a trading volume of 276,597 shares, compared to its average volume of 130,076. The firm has a 50-day moving average price of $33.20 and a 200 day moving average price of $40.76. Simulations Plus has a fifty-two week low of $29.37 and a fifty-two week high of $51.22. The firm has a market capitalization of $613.91 million, a price-to-earnings ratio of 64.50 and a beta of 0.69.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on SLP. Craig Hallum restated a “buy” rating and issued a $56.00 price objective on shares of Simulations Plus in a research note on Wednesday, July 3rd. KeyCorp started coverage on shares of Simulations Plus in a research note on Monday, July 29th. They set an “overweight” rating and a $47.00 price objective for the company. BTIG Research cut their price objective on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a research note on Thursday. William Blair restated an “outperform” rating on shares of Simulations Plus in a research report on Thursday. Finally, JMP Securities began coverage on Simulations Plus in a research report on Tuesday, July 16th. They set a “market perform” rating on the stock. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $54.50.

Insider Activity at Simulations Plus

In related news, Director Walter S. Woltosz sold 20,000 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $35.18, for a total value of $703,600.00. Following the completion of the transaction, the director now owns 3,501,592 shares of the company’s stock, valued at approximately $123,186,006.56. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last quarter, insiders have sold 60,750 shares of company stock worth $2,145,055. 20.90% of the stock is owned by company insiders.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.